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Evaluation of analytical performance of dRAST™ system for direct 
and rapid antimicrobial susceptibility testing on Gram-negative 
and Gram-positive organisms from positive blood cultures
INTRODUCTION
The direct rapid antimicrobial susceptibility test (AST) from QuantaMatrix (dRAST™) is a 
platform using microfluidic chip technology to provide minimal inhibitory concentrations 
(MICs) directly on positive blood culture (PBC) samples within 6 hours. Bacterial growth is 
analyzed at different antibiotic concentrations by time-lapse imaging. 1-2
CONCLUSIONS
AST results obtained with dRAST™ are consistent with routine 
laboratory system Vitek®2. This innovative technology provides 
MICs within 6 hours, directly on PBC, thus saving precious time 
in the management of patients with bacteremia. The addition of 
an expert system on dRAST™ software will allow correction of 
unreliable results and provide comments and rules allowing the 
laboratory to give relevant information to clinicians.
RESULTS
METHODS
The dRAST™ was performed on all PBC directly after Gram staining to determine which 
of the 2 antibiotic panels should be used. We selected the first bacterial isolates from 
each patient's PBC. A total of 148 Gram-negative and 100 Gram-positive panels were 
included in this evaluation. For each strain included, we performed a conventional AST 
with Vitek®2. 
We followed Cumitech 31A to define Categorical Agreement (CA) (≥ 90%), Essential 
Agreement (EA) (≥ 90%), and Major Errors (ME) (< 5%) to calculate analytical 
performance of the dRAST™. 3
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AIM
This study aimed to evaluate the analytical performance of the dRAST™ system for the 
direct AST of bacteria from PBC of patients hospitalized in the University Hospital of Liège 
in comparison to results of conventional AST obtained with Vitek®2.
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Table 1: Evaluation of analytical performance of dRAST™ system for 
direct and rapid AST on Gram-negative organisms from PBC 
compared to conventional AST obtained with Vitek®2
Table 2: Evaluation of analytical performance of dRAST™ system for 
direct and rapid AST on Gram-positive organisms from PBC compared 
to conventional AST obtained with Vitek®2
• 130 Enterobacterales (including 18 ESBL)
• 15 Pseudomonas aeruginosa
• 3 Acinetobacter spp.
148 PBC with
Gram-negative
organisms
• 41 Staphylococcus aureus (including 5 MRSA)
• 36 coagulase negative staphylococci (CoNS)
• 23 Enterococcus spp.
100 PBC with
Gram-positive 
organisms
Figure 1: Summary of PBC strains included in the MIC comparison between dRASTTM
(QuantaMatrix) and Vitek®2 (bioMérieux)
Pseudomonas aeruginosa : main discrepencies with
✓ Imipenem [EA = 60% (9/15), ME = 6,7% (1/15)]
✓ Levofloxacin [EA = 86,7% (13/15), ME = 6,7% (1/15)]
✓ Ceftazidime [EA = 86,7% (9/15), ME= 0% (0/15)]
✓ Discrepancies are probably biased by the small
sample size studied (15 strains)
Gram-positive panel (Staphylococcus spp., 
Enterococcus spp.) : main discrepancies with
✓ Molecules not often used for the treatment of 
staphylococcal bacteremia (fusidic acid, 
erythromycin, clindamycin, rifampicin and 
tetracycline)
✓ Linezolid:
▪ EA  = 63% (63/100) [S. aureus: 51,2% (21/41), 
CoNS: 72,2% (26/36), Enterococcus spp: 69,6% 
(16/23)]
▪ But MIC measured by dRAST™ (between ≤ 0,5 
and 1) and Vitek®2 (between 1 and 2) were
close, allowing to categorize the strains as 
susceptible, with an excellent CA
Figure 2: Evaluation of analytical performance of dRAST™
system for direct and rapid AST on Gram-negative and 
Gram-positive organisms from PBC compared to 
conventional AST obtained with Vitek®2
Enterobacterales :
✓ Very good results
✓ Poorer performance with piperacillin-tazobactam
▪ CA of 88,3% (113/128) 
▪ ME of 8,6% (11/128)
▪ But it is impossible to define the most reliable 
method between dRAST™ and Vitek®2 (none of 
them is considered the reference method)
Compared to Vitek®2, overall performance of dRAST™ showed
EA of 92,1% and CA of 93,4% including 4,3% of ME. For Gram-
negative organisms, EA is of 94,6% and CA is of 94,8% including
3% of ME. For Gram-positive isolates, performance showed EA
of 87,3% and CA of 90,8% including 6,8% of ME.
VITEK®2
dRASTTM
Image 1: schematic 
representation of the 
dRASTTM evaluation in 
parallel with Vitek®2 for each 
PBC included 
